SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Operating Expenses
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Operating Expenses of $3.95 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-09-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-09-24
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. operating expenses for the quarter ending 2026-06-30 was $3.95M, a 1.00% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. operating expenses for the quarter ending 2026-03-31 was $2.22M, a 24.89% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. operating expenses for the quarter ending 2025-12-31 was $2.79M, a 56.90% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. operating expenses for the quarter ending 2025-09-30 was $2.27M, a 25.71% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. operating expenses for fiscal 2025 was $11.92M, a 54.84% increase from fiscal 2024.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. operating expenses for fiscal 2024 was $7.70M, a 30.61% increase from fiscal 2023.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. operating expenses for fiscal 2023 was $5.89M, a 151.40% increase from fiscal 2022.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. operating expenses for fiscal 2022 was $2.34M, a 34.47% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $3.95M 10-Q · filed 2026-09-24 | $6.17M 10-Q · filed 2026-09-24 | $8.95M derived: sum of 3 quarters · filed 2026-09-24 | $11.22M derived: sum of 4 quarters · filed 2026-09-24 | |
| 2026-03-31 | $2.22M 10-Q · filed 2026-05-15 | $5.01M derived: sum of 2 quarters · filed 2026-05-15 | $7.27M derived: sum of 3 quarters · filed 2026-05-15 | $11.18M derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-12-31 | $2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $5.06M derived: sum of 2 quarters · filed 2026-03-31 | $8.97M derived: sum of 3 quarters · filed 2026-09-24 | $11.92M 10-K · filed 2026-03-31 | |
| 2025-09-30 | $2.27M 10-Q · filed 2025-11-13 | $6.18M derived: sum of 2 quarters · filed 2026-09-24 | $9.13M 10-Q · filed 2025-11-13 | $10.91M derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-06-30 | $3.91M 10-Q · filed 2026-09-24 | $6.86M 10-Q · filed 2026-09-24 | $8.64M derived: sum of 3 quarters · filed 2026-09-24 | $11.69M derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-03-31 | $2.95M 10-Q · filed 2026-05-15 | $4.73M derived: sum of 2 quarters · filed 2026-05-15 | $7.78M derived: sum of 3 quarters · filed 2026-05-15 | $9.26M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $4.83M derived: sum of 2 quarters · filed 2026-03-31 | $6.31M derived: sum of 3 quarters · filed 2026-03-31 | $7.70M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $3.05M 10-Q · filed 2025-11-13 | $4.53M derived: sum of 2 quarters · filed 2025-11-13 | $5.92M 10-Q · filed 2025-11-13 | $7.20M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $1.48M 10-Q · filed 2025-08-13 | $2.87M 10-Q · filed 2025-08-13 | $4.15M derived: sum of 3 quarters · filed 2025-08-13 | $5.75M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $1.38M 10-Q · filed 2025-05-08 | $2.67M derived: sum of 2 quarters · filed 2025-05-08 | $4.27M derived: sum of 3 quarters · filed 2025-05-08 | $5.73M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $2.88M derived: sum of 2 quarters · filed 2025-02-26 | $4.35M derived: sum of 3 quarters · filed 2025-02-26 | $5.89M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $1.60M 10-Q · filed 2024-11-13 | $3.06M derived: sum of 2 quarters · filed 2024-11-13 | $4.61M 10-Q · filed 2024-11-13 | $5.14M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $1.47M 10-Q · filed 2024-09-04 | $3.01M 10-Q · filed 2024-09-04 | $3.54M derived: sum of 3 quarters · filed 2024-09-04 | $4.36M derived: sum of 4 quarters · filed 2024-09-04 | |
| 2023-03-31 | $1.54M 10-Q/A · filed 2024-09-04 | $2.08M derived: sum of 2 quarters · filed 2024-09-04 | $2.90M derived: sum of 3 quarters · filed 2024-09-04 | $3.25M derived: sum of 4 quarters · filed 2024-09-04 | |
| 2022-12-31 | $530.34K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-04 | $1.35M derived: sum of 2 quarters · filed 2024-09-04 | $1.71M derived: sum of 3 quarters · filed 2024-09-04 | $2.34M 10-K/A · filed 2024-09-04 | $2.55M 10-K · filed 2023-03-15 |
| 2022-09-30 | $821.47K 10-Q · filed 2023-11-13 | $1.18M derived: sum of 2 quarters · filed 2023-11-13 | $1.81M 10-Q · filed 2023-11-13 | $2.80M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $353.63K 10-Q · filed 2023-08-14 | $992.02K 10-Q · filed 2023-08-14 | $1.98M derived: sum of 3 quarters · filed 2023-08-14 | $2.22M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $638.40K 10-Q · filed 2023-05-25 | $1.63M derived: sum of 2 quarters · filed 2023-05-25 | $1.87M derived: sum of 3 quarters · filed 2023-05-25 | ||
| 2021-12-31 | $988.54K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $1.23M derived: sum of 2 quarters · filed 2023-03-15 | $1.74M 10-K · filed 2023-03-15 | ||
| 2021-09-30 | $242.12K 10-Q · filed 2022-11-14 | $754.45K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |